JMT601
Phase 2Biologic
JMT601 is one of 60 biologic programs targeting Lymphoma. It is currently in Phase 2.
2
Indications
2
Total Trials
2
Active Trials
59
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
1774 competitors in Lymphoma
#DrugCompanyPhaseTrials
1Blenoxane
SSequus Pharmaceuticals
Preclinical
Oncaspar
SServier
Preclinical
Zofran
NovartisPreclinical
Norvir
AbbViePreclinical
Wellcovorin
GGlaxo Dba Glaxosmithkline
Preclinical
Tafasitamab
IncytePreclinical
JMT601
SShanghai JMT-Bio Inc.
Phase 2
Nuvigil
NNuvo Research GmbH
Preclinical
Systemic Therapy
Bristol-Myers SquibbPreclinical
VP-16
FFundamenta Therapeutics, Ltd.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for JMT601. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 2[1]
- Company
- SShanghai JMT-Bio Inc.